Print ISSN 2229-7456

LIPT

95



International Journal of Pharmacy & Therapeutics

Journal homepage: www.ijptjournal.com

FORMULATION DEVELOPMENT AND CHARACTERISATION OF PIROXICAM GEL USING WATER SOLUBLE POLYACRYLAMIDE POLYMER

S.L. Dheivanai¹*, G. Jeevaprakash², S. Selvakumar¹, M. Lakshmana doss¹, V. Rajalakshmi¹, Mrinmay das²

¹ Department of pharmacy, Jagan's college of pharmacy, Nellore, Andhra Pradesh, India. ² Department of pharmacy, S.Chaavan College of pharmacy, Nellore, Andhra Pradesh, India.

ABSTRACT

The high molecular weight water soluble homopolymer type of acrylamide was reported to obtain very high viscosity in low concentration, transparency, film forming properties and useful in formation of transdermal gel. The piroxicam gels were prepared by using different concentration of polyacrylamide for topical drug delivery with an aim to gradually increase transparency and spreadability. These preparations were further compared with marketed known Dolonex gel. Spreadability and consistency of polyacrylamide gel containing piroxicam gel (S9) were 6.5g.cm/sec and 5mm as compared to 5.5g.cm/sec and 10mm respectively of known marketed gel, indicating good spreadability nature and consistency of the prepared gel (S9). The transparency nature of prepared batch (S9) was good as compared to the known marketed gel. The percent drug release was 97.85% and 98.84% from S9 and known marketed gel respectively. No irritation was felt in the skin irritation test. Stability studies' conducting under accelerated condition was shown satisfactory results. It can be concluded that polyacrylamide gel containing piroxicam gel showed good consistency, spreadability, homogeneity and stability and had wider prospect for topical preparations.

Keywords:- Topical drug delivery, Water soluble polymer, Piroxicam gel, Transdermal gel, Polyacrylamide.

INTRODUCTION

Transdermal gel preparations are intended for superficial skin application (Sera UV *et al.*, 2006) or to some mucosal surfaces for local action (Shivhare UD *et al.*, 2009) or skin penetration of medicament (Gupta GD *et al.*, 1999) or for their soothing or protective action (Williams AC *et al.*, 2003). Gels are typically formed from a liquid phase that has been thickened with other

Corresponding Author

S.L. Dheivanai Email:- dheiva.78@gmail.com ingredients (Golinkin HS *et al.*, 1979). The continuous liquid phase allows free diffusion of molecules through the polymers scaffold (King DJ *et al.*, 1989) and hence release might be equivalent to that from a simple solution (Rowland CD *et al.*, 1999 and Fried JR *et al.*, 1998). The (NSAID's) nonsteroidal anti-inflammatory drugs are having excellent anti-inflammatory and analgesic activity but NSAID's produces GIT ulceration, liver and kidney trouble produced in case of oral administration. In view to reduce adverse drug reaction associated with oral formulations, we have prepared as transdermal gel.

MATERIALS AND METHOD MATERIALS

Piroxicam was purchased from Indian Drug House (Hyderabad, India). Polyacrylamide homopolymer were purchased by Suyog Chemicals Ltd (Nagpur, India). Sodium metabisulphite AR grade was procured by Sigma Pvt. Ltd. (Mumbai, India). All other ingredients were of analytical grade. Dolonex gel was purchased from market.

METHOD

Procedure of gel preparation

About 5g of piroxicam was weighed and dissolved in 5g of isopropyl alcohol, to this solution, specified quantity of glycerin or propylene glycol or cocodiethanolamide was added and dissolved (solution A). Weighed quantity of polyacrylamide was added to the 75g of distilled water containing 0.1g of sodium metabisulfide used as antioxidant and continuously stirred to dissolve the same (solution B). Solution A and B were mixed thoroughly and the final weight was made upto 100g. (Table no.1).

Precipitation or turbidity occurs in some of the batches (S1, S2, S3, S4, S5 and S6) of polyacrylamide gel containing piroxicam which has been due to the incompatibility in the system due to presence of glycerin or propylene glycol. Hence, these batches were discarded finally and remaining batches (S7, S8 and S9) were considered for further study.

EVALUATION PARAMETERS

Effective evaluation of polyacrylamide gel containing piroxicam and marketed gel

The above prepared polyacrylamide gel containing piroxicam and marketed gel were subjected to evaluation for the following parameters:

pН

The pH of the various gel preparations was determined by using digital pH meter (Table no. 2).

Spreadability

It was estimated by wooden block and glass slide apparatus. Weights about 20g were added to the sterile pan and the time was accurately noted for upper slide (movable) to separate completely from the fixed slides (Table no. 2).

Spreadability was calculated by the formula: S = M.L / T

Where.

S = Spreadability

M = Weight tide to upper slide

L = Length of glass slide

 $T=\mbox{Time}$ taken to separate the slide completely from each other

Consistency

The estimation of consistency of the prepared gels was done by dropping a cone attached to a holding rod from a fixed distance of 10cm in other way that it should fall down on the centre of the glass cup was filled with the gel. The penetration by the cone was accurately measured from the surface of the gel to the tip of the cone inside of the gel (William L *et al.*, 2000). The distance traveled by cone in the period was noted down after 10sec (Table no. 2).

Homogeneity

All developed gels were properly tested for homogeneity by visual inspection after gels has been set in the container. These were tested for their appearance and presence of any aggregates (Table no. 2).

Skin irritation test

Test for irritation was carefully performed as per guidelines after getting informed consent on human volunteers. For each gel, five volunteers were selected and 1.0g of formulated gel was applied on an area of 2 square inch to side of hand. The volunteers were examined for lesions or irritation (Table no. 2).

Drug content

A specified quantity (100mg) of developed gel and marketed gel were taken and dissolved in 100ml of phosphate buffer of pH 6.8. The volumetric flask containing gel solution was shaken for the period 2 hrs on mechanical shaker in order to get absolute solubility of drug. This solution was filtered and estimated spectrophotometrically at 276.0nm using phosphate buffer (pH 6.8) as blank (Table no. 2).

Accelerated stability studies

All the selected formulations were subjected to a stability testing for the period of three months as per ICH norms at a temperature of $40^{\circ} \pm 2^{\circ}$ (ICH). All selected formulations were analyzed for the changes in appearance, pH or drug content by procedure stated earlier (Table no. 3).

Permeability studies

Phosphate buffer of pH 6.8 was used for in vitro release as receptor medium (Sahoo SK *et al.*, 2006). The pretreated skin of albino mice was used in Franz diffusion cell. The gel sample was applied on the skin of animal and then fixed in between donor and receptor compartment of quality diffusion cell. The receptor compartment contained phosphate buffer (100ml) of pH 6.8. The temperature of diffusion medium was thermostatically controlled at $37^{\circ} \pm 1^{\circ}$ by surrounding water in jacket and the medium was

continuously stirred by magnetic stirrer at speed of 500rpm. The sample at predetermined intervals were withdrawn and replaced by equal volume of freshly

prepared fluid. The samples withdrawn were spectrophotometrically measured at 276 nm against their blank (Table no. 4 and Fig-1).

Table 1. Composition and concentration of piroxicam gel

| Batch No | Polymer (gm) | Polymer (gm) | Isopropyl alcohol (gm) | Sodium Metabisulphite (gm) | Glycerin (g) | Propylenegl ycol (gm) | Cocodiethanol amide (gm) | Distilled water (gm) |
|-------------|-----------------|-----------------|------------------------------|----------------------------------|-----------------|-----------------------------|--------------------------------|----------------------------|
| S1 | 5 | 3 | 5 | 0.1 | 1 | | | Upto 100 |
| S2 | 5 | 3 | 5 | 0.1 | 3 | | | Upto 100 |
| S3 | 5 | 3 | 5 | 0.1 | 9 | | | Upto 100 |
| S4 | 5 | 3 | 5 | 0.1 | | 1 | | Upto 100 |
| S 5 | 5 | 3 | 5 | 0.1 | | 3 | | Upto 100 |
| S6 | 5 | 3 | 5 | 0.1 | | 9 | | Upto 100 |
| S7 | 5 | 3 | 5 | 0.1 | | | 0.1 | Upto 100 |
| S8 | 5 | 3 | 5 | 0.1 | | | 0.3 | Upto 100 |
| S9 | 5 | 3 | 5 | 0.1 | | | 0.9 | Upto 100 |

Table 2. Each value of evaluation parameters of developed gel and marketed gel


| Batch No | рН | Spreadability (g.cm/sec) | Consistency (60 sec) | Homogeneity | Skin irritation test | Drug content (%) |
|--------------|-----|-----------------------------|-------------------------|-------------|-------------------------|---------------------|
| S 7 | 6.8 | 6.0 | 5mm | Good | nil | 99.94 |
| S8 | 6.8 | 6.5 | 5mm | Good | Nil | 99.93 |
| S9 | 6.8 | 7.0 | 5mm | Good | nil | 99.98 |
| Marketed Gel | 6.8 | 5.5 | 10mm | Good | nil | 99.90 |

| S.No | Batches | Months | Appearance | pH | Drug Content (%) |
|------|--------------|--------|------------|-----|------------------|
| 01 | | 0 | Clear | 6.8 | 99.45 |
| | F7 | 1 | Clear | 6.6 | 97.74 |
| | | 2 | Clear | 6.7 | 98.86 |
| | | 3 | Clear | 6.6 | 96.62 |
| 02 | F8 | 0 | Clear | 6.7 | 97.48 |
| | | 1 | Clear | 6.8 | 98.64 |
| | | 2 | Clear | 6.6 | 96.48 |
| | | 3 | Clear | 6.6 | 99.46 |
| 03 | | 0 | Clear | 6.7 | 96.98 |
| | F9 | 1 | Clear | 6.8 | 98.26 |
| | | 2 | Clear | 6.6 | 97.28 |
| | | 3 | Clear | 6.7 | 99.97 |
| 04 | Marketed gel | 0 | Clear | 6.6 | 98.40 |
| | | 1 | Clear | 6.5 | 99.89 |
| | | 2 | Clear | 6.8 | 95.60 |
| | | 3 | Clear | 6.7 | 96.48 |

Table 4. Permeability studies of S9 and marketed gel

| S.No | Time Interval | Medium pH | %Drug release (min) | |
|------|---------------|-----------|---------------------|----------------------|
| | | | Batch S9 | Marketed Preparation |
| 1 | 30 | 6.8 | 55.42 | 56.24 |
| 2 | 60 | 6.8 | 78.68 | 78.92 |
| 3 | 90 | 6.8 | 88.46 | 90.57 |
| 4 | 120 | 6.8 | 97.85 | 98.84 |

Fig 1. Drug permeability release profile of S9 and Piroxicam gel formulation



RESULTS AND DISCUSSION

The pH values of all formulated (S6, S7, S8 and S9) and marketed gel was 6.8. The values of measured spreadability indicate that the gel is easily spreadable by small amount of shear. Spreadability of marketed gel was 5.5g.cm/sec while S9 was 6.5g.cm/sec, indicating spreadability of polyacrylamide containing piroxicam gel was good as compared to the marketed gel. The consistency reflects the capacity of the gel, this has been get ejected in uniform and desired quantity when the tube is squeezed. Consistency in shake of distance traveled by cone was 5mm of all developed batches when compared to 10mm of marketed gel. Consistency is inversely proportional to the distance traveled by falling cone. Though, the consistencies of polyacrylamide gel containing piroxicam were better as compared with marketed gel. All formulated and marketed gel showed good homogeneity with absence of lumps. The formulated preparations showed much clear and transparent when compared to marketed gel. The skin irritation studies of prepared piroxicam gel were carried out on human volunteers and that confirmed the absence of any irritation on the applied surface. During the stability studies the visible appearance was clear and no significant variation in pH which was observed. Considering the accelerated stability studies and physiochemical parameters, batch S9 was selected for in vitro permeability release studies as well as compared with the marketed gel. In vitro Permeability study shown that permeation studies of S9 and marketed gel were comparable. It was concluded that polyacrylamide gel containing piroxicam (batch S9) produced better spreadability nature and consistency when compared to marketed piroxicam gel. The prepared S9 gel showed good homogeneity, no skin irritation, good stability and in vitro permeability was comparable with known marketed gel. The polyacrylamide form completely water washable gel due to its water solubility and has wider prospects to be used as a transdermal drug delivery system (Narin GJ et al., 1997).

CONCLUSION

The prepared polymer being macromolecules of very high molecular weight remain unabsorbed on the skin and from our studies it can be concluded that polyacrylamide can be used for various topical dosage form for external application. It has been proved that optimized batch produces the gel with good consistency, homogeneity, spreadability and stability. Hence, the polymer is water soluble, consequently, it forms water

REFERENCES

British Pharmacopoeia. International Publication, Vol-II, 1993.

Fried JR. Polymer Science and Technology. Prentice-Hall, New Jersey. 1, 1998.

Golinkin HS. Process for fracturing well formations using aqueous gels. US Patent No. US 4137182, 1, 1979.

Gupta GD, Gound RS. Release rate of nimesulide from different gellants. Indian J Pharm Sci. 61, 1999, 229-234.

King DJ, Noss RR. Toxicity of polyacrylamide and acrylamide polymers. Environ Toxi Chem, 16, 1989, 1-4.

Narin GJ. Encyclopedia of Pharmaceutical Technology. Marcel Decker, New Work, 1, 1997.

Rowland CD, Burton JR. A review on toxicity of various hydrophilic polymers. Environ Toxi Chem., 19, 1999, 2136-2139.

Sahoo SK, Samal AR. Estimation and evaluation of secnidazole. The Indian Pharmacist, 5 (46), 2006, 73.

Sera UV, Ramana MV. In vitro skin absorption and drug release – a comparison of four commercial hydrophilic gel preparations for topical use. *The Indian Pharmacist*, 73, 2006, 356-360.

Shivhare UD, Jain KB. Formulation development and evaluation of diclofenac sodium transdermal gel using water soluble polyacrylamide polymer. *Digest Journal of Nanomaterials and Biostructures*, 1, 2009, 285-290.

William L, Remington: The Science and Practice of Pharmacy. *Mack Publishing Company. Easton*, PA, 20th edition, 2000. Williams AC. Topical and Transdermal Formulation. *Pharmaceuticals Press Published*, New York, 1, 2003, 1-5.

washable gel and has been wider prospects to be used as a

college of pharmacy and S.Chaavan College of pharmacy

(Nellore, Andhra Pradesh, India) for providing necessary

Authors are thankful to Management of Jagan's

transdermal topical drug delivery dosage form.

facilities to carry out this research work.

ACKNOWLEDGEMENT